5AM Venture Management LLC Acquires New Holdings in Alector, Inc. (NASDAQ:ALEC)

5AM Venture Management LLC bought a new position in shares of Alector, Inc. (NASDAQ:ALEC - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 995,841 shares of the company's stock, valued at approximately $1,882,000. Alector accounts for 0.4% of 5AM Venture Management LLC's holdings, making the stock its 28th biggest holding. 5AM Venture Management LLC owned approximately 1.02% of Alector as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its stake in shares of Alector by 71.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company's stock valued at $28,000 after purchasing an additional 6,096 shares during the period. Vontobel Holding Ltd. increased its holdings in shares of Alector by 127.3% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock valued at $47,000 after acquiring an additional 14,000 shares in the last quarter. Apollon Wealth Management LLC acquired a new position in shares of Alector during the fourth quarter worth approximately $47,000. RPO LLC bought a new position in shares of Alector in the 4th quarter worth $50,000. Finally, Intech Investment Management LLC boosted its stake in Alector by 83.5% during the 4th quarter. Intech Investment Management LLC now owns 35,382 shares of the company's stock valued at $67,000 after purchasing an additional 16,096 shares during the last quarter. 85.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ALEC. HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Alector in a research report on Thursday, February 27th. Morgan Stanley reissued an "underweight" rating and issued a $1.50 price target (down from $3.00) on shares of Alector in a report on Friday, March 7th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Alector has a consensus rating of "Hold" and an average price target of $3.50.

Alector Price Performance

NASDAQ:ALEC traded down $0.02 during mid-day trading on Wednesday, reaching $1.04. 336,247 shares of the company's stock traded hands, compared to its average volume of 806,169. The company has a 50 day moving average price of $1.21 and a 200-day moving average price of $2.18. The firm has a market capitalization of $103.49 million, a price-to-earnings ratio of -0.61 and a beta of 0.76. Alector, Inc. has a 12-month low of $0.87 and a 12-month high of $6.78.

Alector (NASDAQ:ALEC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.59. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The company had revenue of $54.24 million during the quarter, compared to analyst estimates of $20.41 million. As a group, analysts forecast that Alector, Inc. will post -1.88 EPS for the current year.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.